Therapy Detail

Therapy Name Enzastaurin
Therapy Description

Enzastaurin (LY317615) is a selective inhibitor PKC-beta, with activity against other PKC isoforms at higher concentrations, which decreases downstream signaling and potentially results in reduced tumor growth (PMID: 16103100, PMID: 17671157, PMID: 22253748).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Enzastaurin LY317615 PKC beta Inhibitor 6 Enzastaurin (LY317615) is a selective inhibitor PKC-beta, with activity against other PKC isoforms at higher concentrations, which decreases downstream signaling and potentially results in reduced tumor growth (PMID: 16103100, PMID: 17671157, PMID: 22253748).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
GNAQ Q209L uveal melanoma sensitive Enzastaurin Preclinical - Cell culture Actionable In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22253748). 22253748
GNAQ Q209P uveal melanoma sensitive Enzastaurin Preclinical - Cell culture Actionable In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22253748). 22253748
Unknown unknown colon cancer not applicable Enzastaurin Preclinical - Cell line xenograft Actionable In a preclinical study, Enzastaurin (LY317615) demonstrated efficacy by suppressing proliferation of cultured cells and growth in cell line xenograft models of colon cancer (PMID: 16103100). 16103100
Unknown unknown glioblastoma multiforme not applicable Enzastaurin Preclinical - Cell line xenograft Actionable In a preclinical study, Enzastaurin (LY317615) demonstrated efficacy by suppressing proliferation of cultured cells and growth in cell line xenograft models of glioblastoma (PMID: 16103100). 16103100
Clinical Trial Phase Therapies Title Recruitment Status
NCT03263026 Phase III CHOP + Rituximab Enzastaurin Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1 Recruiting